| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Nature Reviews Cancer | 2016 | 1.4K |
| Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America | Clinical Infectious Diseases | 2016 | 1.3K |
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial | Lancet Oncology, The | 2016 | 783 |
| REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants | American Journal of Human Genetics | 2016 | 722 |
| Targeting the cancer epigenome for therapy | Nature Reviews Genetics | 2016 | 649 |
| Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial | Journal of Psychopharmacology | 2016 | 649 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2016 | 580 |
| Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment | Mayo Clinic Proceedings | 2016 | 543 |
| Prostate Cancer, Version 1.2016 | Journal of the National Comprehensive Cancer Network: JNCCN | 2016 | 473 |
| Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial | Lancet Oncology, The | 2016 | 450 |
| Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures | Genome Biology | 2016 | 391 |
| In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform | Frontiers in Bioengineering and Biotechnology | 2016 | 386 |
| Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited instruments | Ageing Research Reviews | 2016 | 366 |
| Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors | Kidney International | 2016 | 353 |
| Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer | Journal of Clinical Oncology | 2016 | 338 |
| Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells | Science | 2016 | 327 |
| Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma | Cancer Cell | 2016 | 324 |
| Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer | Journal of Clinical Oncology | 2016 | 322 |
| Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy | | 2016 | 311 |
| Transcription factors as readers and effectors of DNA methylation | Nature Reviews Genetics | 2016 | 303 |
| NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016 | Journal of the National Comprehensive Cancer Network: JNCCN | 2016 | 272 |
| Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial | Lancet Oncology, The | 2016 | 269 |
| Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer | Oncotarget | 2016 | 250 |
| Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets | Clinical Cancer Research | 2016 | 242 |
| Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology | 2016 | 235 |
